The role of platelet P2Y 12 receptors in inflammation
British Journal of Pharmacology · 2024-02 · 181 (4) · 515-531
DOI: 10.1111/bph.16256 ↗At a glance
Übersichtsarbeit in British Journal of Pharmacology, published online on 2023-11-02. Written by William A E Parker and 1 co-authors. Institution: Cardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield, Sheffield, UK. Major MEDLINE topics: Platelet Aggregation Inhibitors, Purinergic P2Y Receptor Antagonists. Cited 37 times so far (Crossref); 170 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: British Heart Foundation.
Abstract (original language)
Inflammation is a complex pathophysiological process underlying many clinical conditions. Platelets contribute to the thrombo‐inflammatory response. Platelet P2Y 12 receptors amplify platelet activation, potentiating platelet aggregation, degranulation and shape change. The contents of platelet alpha granules, in particular, act directly on leucocytes, including mediating platelet–leucocyte aggregation and activation via platelet P‐selectin. Much evidence for the role of platelet P2Y 12 receptors in inflammation comes from studies using antagonists of these receptors, such as the thienopyridines clopidogrel and prasugrel, and the cyclopentyltriazolopyrimidine ticagrelor, in animal and human experimental models. These suggest that antagonism of P2Y 12 receptors decreases markers of inflammation with some evidence that this reduces incidence of adverse clinical sequelae during inflammatory conditions. Interpretation is complicated by pleiotropic effects such as those of the thienopyridines on circulating leucocyte numbers and of ticagrelor on adenosine reuptake. The available evidence suggests that P2Y 12 receptors are prominent mediators of inflammation and P2Y 12 receptor antagonism as a potentially powerful strategy in a broad range of inflammatory conditions. LINKED ARTICLES This article is part of a themed issue on Platelet purinergic receptor and non‐thrombotic disease. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.4/issuetoc
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Cardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield, Sheffield, UK.
- NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
ORCID profiles: William A E Parker, Robert F Storey
Funding
- British Heart Foundation
Cite
APA
Parker, W. A. E., & Storey, R. F. (2024). The role of platelet P2Y 12 receptors in inflammation. British Journal of Pharmacology, 181(4), 515-531. https://doi.org/10.1111/bph.16256
Vancouver
Parker WAE, Storey RF. The role of platelet P2Y 12 receptors in inflammation. British Journal of Pharmacology. 2024;181(4):515-531. doi:10.1111/bph.16256
BibTeX
@article{Parker2024,
author = {Parker, William A E and Storey, Robert F},
title = {The role of platelet P2Y 12 receptors in inflammation},
journal = {British Journal of Pharmacology},
year = {2024},
volume = {181},
number = {4},
pages = {515--531},
doi = {10.1111/bph.16256}
}
EUVIMED